Medmain is developing a marketplace for pathological image diagnosis, including Deep Learning based diagnosis.
Pathologists, a type of specialist medical practitioners who examine tissues of patients to make a final diagnosis, are required in any hospital. However, there is a shortage of them, and patients have to wait for a few weeks to obtain their results. We will solve this problem with “PidPort” and create a society where one can have a high-quality pathological diagnosis from any location.
Location: Japan, Minato
Total raised: $10.4M
Investors 2
| Date | Name | Website |
| - | Dogan Beta | dogan.vc/ |
| - | J-Startup | j-startup.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.08.2020 | Series A | $10.4M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 17.04.2024 | Medmain, a pathological AI developer, raises 850 million yen... | Medmain, a pathological AI developer, raises 850 million yen (total of 2.05 billion yen) in Series A... | re-how.net... |
| 02.11.2023 | 「久留米大学医学部」が教育・研究用途でデジタル病理支援クラウド「PidPort」を活用... | デジタル病理支援ソリューション「PidPort」を提供するメドメイン株式会社 ( 本社：福岡県福岡市、代表取締役CEO： 飯塚 統、以下「メドメイン」)は、教育および研究用途において、久留米大学様に「... | prtimes.jp... |
| 12.09.2023 | Medmain Inc. Has Been Selected for the U.S. Market Gateway A... | FUKUOKA, Japan, Sept. 12, 2023 /PRNewswire/ -- Medmain Inc. (https://en.medmain.com), a Japanese med... | en.prnasia... |
| 16.03.2022 | Medmain Inc. Succeeded in developing pathological AI that ac... | Medmain Inc. Succeeded in developing pathological AI that accelerates cervical cancer screening with... | re-how.net... |